Flerie

AnaCardio has successfully completed Part A of the phase 1b/2a GOAL-HF1 study of its novel, selective oral ghrelin receptor agonist in patients with heart failure. AC01 was well-tolerated, there was clear target engagement and exploratory pharmacodynamic measurements indicated increased contractility. This will be further evaluated in Part B of the ongoing trial, in the cohort expansion phase, due to start in early 2025.

In conjunction with this important clinical milestone, the company has completed a SEK 205 M Series A extension financing round, co-led by Novo Holdings, Pureos Bioventures and Sound Bioventures, with participation from current investors Flerie, Industrifonden and Fredrik and Ann-Helene Ljungström.

“We are pleased that given these encouraging results, AC01 can now move into the next phase of clinical development: We also welcome the new investors which further strengthens the syndicate. AnaCardio is now in an excellent position and one step closer to bringing a novel contractile agent to heart failure patients”, commented Mark Quick, Partner at Flerie.